rituximab + bendamustine + cytarabine

Rituximab + bendamustine + cytarabine is a combination chemotherapy regimen primarily used for the treatment of mantle cell lymphoma (MCL), including both newly diagnosed and relapsed/refractory cases. Rituximab is a monoclonal antibody targeting CD20 on B cells, leading to their destruction via immune-mediated mechanisms. Bendamustine is an alkylating agent that causes DNA crosslinking and cell death, while cytarabine is an antimetabolite that inhibits DNA synthesis by acting as a pyrimidine analog. The combination has demonstrated high overall and complete response rates in clinical trials for MCL, with manageable toxicity profiles—mainly hematologic toxicities such as thrombocytopenia and neutropenia[1][4][5]. This regimen may be used in both transplant-eligible and -ineligible patients; it can serve as induction therapy prior to autologous stem cell transplantation or as definitive therapy in older or less fit patients[2][7]. The combination leverages the synergistic effects of these agents against malignant B cells.

Other names

R-BACRBAC500RBAC-500RBAC 500